Purpose Post-prostatectomy urinary incontinence (PPUI) treatment ranges from conservative measures to invasive surgery. Bulkamid is a urethral bulking agent used widely in female incontinence but has not been used in men. We aimed to assess the safety and efficacy of male Bulkamid injections for PPUI. Methodology This is a retrospective cohort study of men undergoing Bulkamid urethral bulking for PPUI. Men with incontinence from other causes were excluded. Bulkamid was injected transurethrally at the submucosal membranous urethra with 4 deposits or until mucosal coaptation was achieved. Measured outcomes included post-procedural complications and number of daily pads. Failure was defined as further surgery excluding repeat Bulkamid. Results 16 men underwent Bulkamid, with 24 procedures (5 men had a repeat procedure and 1 underwent 4). Median age was 70.5 years (IQR 66-73) and follow up was 10 months (3-37). 2 men developed AUR, with successful TOV after 3 days. There were no other complications. Initial median daily pad use was 2 (1-3). 10 men had decreased pad use, 1 unchanged, and 5 increased. Median change in pad number was −1 (−1.25-+1). In the 12 men not requiring further surgery, median initial pad use was 1.5 (1-3) and median decrease of 1 (1-1.6). Median final pad use was 0.25 (0-1.5). 7 men were pad-free. 4 men required further invasive surgery. 2 had prior radiotherapy. 3 men had reported initial decrease in pad use. Median time to other surgery was 13 months (6-23.5). Conclusion Male Bulkamid is safe with minimal complications. Success rate is promising, with an encouraging number of men pad-free or requiring fewer pads, or delaying more invasive surgery. We expect efficacy to improve as experience increases.